Valneva SE (NASDAQ:VALN - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $6.86, but opened at $7.11. Valneva shares last traded at $7.31, with a volume of 860 shares traded.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a "buy" rating and issued a $17.00 price objective on shares of Valneva in a research report on Friday, February 28th.
Check Out Our Latest Report on VALN
Valneva Price Performance
The business has a fifty day simple moving average of $5.97 and a 200-day simple moving average of $5.61. The stock has a market capitalization of $573.70 million, a P/E ratio of -54.31 and a beta of 1.93. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78.
Institutional Investors Weigh In On Valneva
An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA bought a new stake in Valneva SE (NASDAQ:VALN - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 19,244 shares of the company's stock, valued at approximately $84,000. 11.39% of the stock is owned by institutional investors and hedge funds.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Read More
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
